A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF
Steven R. Whittaker(Institute of Cancer Research), Caroline J. Springer(Cancer Research Center)
Cited by 25
Related Papers
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
|Cancer Cell|2014|209
The Cyclin-dependent Kinase Inhibitor CYC202 (<b><i>R</i></b>-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway
|Cancer Research|2004|194
Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates
|Advanced Drug Delivery Reviews|2001|177